Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sonrotoclax TFA is an orally available and highly potent and selective Bcl-2 inhibitor of WT and G101V mutants with antitumor activity for the study of hematologic malignancies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $195 | In Stock | |
5 mg | $483 | In Stock | |
10 mg | $692 | In Stock | |
25 mg | $1,080 | In Stock |
Description | Sonrotoclax TFA is an orally available and highly potent and selective Bcl-2 inhibitor of WT and G101V mutants with antitumor activity for the study of hematologic malignancies. |
In vivo | A once-daily oral dose of 5-50 mg/kg Sonrotoclax TFA for 42 days exhibited antitumor activity and effectively inhibited tumor growth in a female NCG mouse model suffering from acute lymphoblastic leukemia (ALL) xenografts. [1] |
Alias | Sonrotoclax TFA(2383086-06-2 Free base), BGB 11417 TFA |
Molecular Weight | 1004.12 |
Formula | C51H60F3N7O9S |
Smiles | CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC(N(=O)=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C.OC(C(F)(F)F)=O |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.